The 10-second takeaway
For the quarter ended Dec. 31 (Q4), C.R. Bard met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue improved and GAAP earnings per share dropped.
Gross margins contracted, operating margins expanded, and net margins shrank.
CR Bard reported revenue of $751.9 million. The 17 analysts polled by S&P Capital IQ predicted sales of $748.5 million. Sales were 4.9% higher than the prior-year quarter's $717.1 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions.
Non-GAAP EPS came in at $1.70. The 21 earnings estimates compiled by S&P Capital IQ predicted $1.68 per share on the same basis. GAAP EPS of $1.30 for Q4 were 11% lower than the prior-year quarter's $1.46 per share.
Source: S&P Capital IQ. Quarterly periods. Figures may be non-GAAP to maintain comparability with estimates.
For the quarter, gross margin was 62.5%, 70 basis points worse than the prior-year quarter. Operating margin was 28.2%, 40 basis points better than the prior-year quarter. Net margin was 15.1%, 390 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $730.8 million. On the bottom line, the average EPS estimate is $1.56.
Next year's average estimate for revenue is $3.04 billion. The average EPS estimate is $6.65.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 264 members out of 276 rating the stock outperform, and 12 members rating it underperform. Among 103 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 101 give C.R. Bard a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on C.R. Bard is hold, with an average price target of $86.93.
The health-care investing landscape is littered with also-rans and a few major winners. Is C.R. Bard the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company Fool co-founder David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add C.R. Bard to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.